Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Research & Development

Product Pipeline

Targeted Approach To

Rare Diseases

News & Events

September 29, 2017

Proteus Syndrome Phase 1 Data Presentation

August 13, 2018

ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK

September 13, 2018

Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)

More News & Events »